Pivotal phase III study of T cell vaccine Tcelna in patients with relapsing-remitting multiple sclerosis.

Trial Profile

Pivotal phase III study of T cell vaccine Tcelna in patients with relapsing-remitting multiple sclerosis.

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Imilecleucel-T (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Acer Therapeutics; Opexa Therapeutics
  • Most Recent Events

    • 19 Sep 2017 According to a Acer Therapeutics media release, Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics.
    • 08 Nov 2011 Opexa plans to initiate a phase IIb trial in patients with secondary progressive multiple sclerosis, while remaining committed to further advancing the product in relapsing-remitting multiple sclerosis at a later date.
    • 06 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top